FMR LLC & Abigail Johnson Disclose 8.239% Stake in Alnylam Pharma
Ticker: ALNY · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**FMR LLC and Abigail Johnson now own 8.239% of Alnylam Pharma, a significant institutional stake.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their holdings in Alnylam Pharmaceuticals Inc. As of December 31, 2023, they collectively beneficially own 10,342,397 shares of common stock, representing 8.239% of the company. This is an amendment to a previous filing, indicating a change in their ownership stake, which matters to investors as large institutional holdings can influence stock stability and market perception.
Why It Matters
Large institutional ownership by firms like FMR LLC can signal confidence in a company's future, potentially providing a floor for the stock price and attracting other investors.
Risk Assessment
Risk Level: low — This filing indicates a stable, large institutional holding, which generally reduces volatility risk for the stock.
Analyst Insight
Investors should note the continued significant institutional ownership by FMR LLC, which suggests long-term confidence in Alnylam Pharmaceuticals. This filing is an update, not a new position, so it primarily confirms existing institutional interest.
Key Numbers
- 10,342,397 — Shares Beneficially Owned (Total common stock shares held by FMR LLC and Abigail P. Johnson in Alnylam Pharmaceuticals Inc.)
- 8.239% — Percent of Class (The percentage of Alnylam Pharmaceuticals Inc.'s common stock owned by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person and principal owner of FMR LLC
- ALNYLAM PHARMACEUTICALS, INC. (company) — subject company whose stock is being reported
- 10,342,397 (dollar_amount) — total shares beneficially owned
- 8.239% (dollar_amount) — percentage of class owned
Forward-Looking Statements
- FMR LLC will maintain a significant stake in Alnylam Pharmaceuticals Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
Who are the reporting persons in this SC 13G/A filing?
The reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing.
What is the total number of shares beneficially owned by the reporting persons?
FMR LLC and Abigail P. Johnson collectively beneficially own 10,342,397 shares of ALNYLAM PHARMACEUTICALS INC common stock, as detailed in Item 4(a) for FMR LLC and Item 7 for Abigail P. Johnson.
What percentage of ALNYLAM PHARMACEUTICALS INC's common stock do the reporting persons own?
The reporting persons own 8.239% of the class of ALNYLAM PHARMACEUTICALS INC common stock, as indicated in Item 4(b) for FMR LLC and Item 11 for Abigail P. Johnson.
What is the CUSIP number for ALNYLAM PHARMACEUTICALS INC common stock?
The CUSIP number for ALNYLAM PHARMACEUTICALS INC common stock is 02043Q107, as listed in Item 2(e).
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).